MedTrace Logo

Cinnamon Bark, Water-Soluble Cinnamon Extract, and Metformin for Treatment of Type 2 DM.

NCT01302743 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2017-06-26

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess whether Cinnamon bark or water-soluble cinnamon is an effective nutraceutical for the initial treatment of diabetes when compared to standard therapy of Metformin.

Conditions

Interventions

DRUG

Group 1: Metformin

Group 1: Will receive oral extended-release Metformin 1000 mg once a day for 90 days

DIETARY_SUPPLEMENT

Group 2: Cinnamon Bark

Group 2: Will receive Cinnamon Bark 1000 mg once a day for 90 days

DIETARY_SUPPLEMENT

Group 3: Cinnulin PF

Group 3: Will receive Cinnulin PF 500 mg once a day for 90 days.

Sponsors & Collaborators

  • Mike O'Callaghan Military Hospital

    lead FED

Principal Investigators

  • Paul Crawford, M.D. · Mike O'Callaghan Federal Hospital/Nellis Air Force Base

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01302743 on ClinicalTrials.gov